Gout, urate-lowering drugs, and risk of cardiovascular disease: can we clinically trust in the adjusted real-life data?

被引：4
作者：
Borghi, Claudio [1 ]
Fiorini, Giulia [1 ]
机构：
[1] Univ Bologna, Dept Med & Surg Sci, IRCCS S Orsola, Via Albertoni 15, I-40139 Bologna, Italy
来源：
EUROPEAN HEART JOURNAL | 2021年 / 42卷 / 44期
关键词：
HYPERURICEMIA; ALLOPURINOL;
D O I：
10.1093/eurheartj/ehab667
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4589 / 4591
页数：3
相关论文
共 14 条
[1]   Definition of hyperuricemia and gouty conditions [J].
Bardin, Thomas ;
Richette, Pascal .
CURRENT OPINION IN RHEUMATOLOGY, 2014, 26 (02) :186-191
[2]   Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease [J].
Borghi, Claudio ;
Agabiti-Rosei, Enrico ;
Johnson, Richard J. ;
Kielstein, Jan T. ;
Lurbe, Empar ;
Mancia, Giuseppe ;
Redon, Josep ;
Stack, Austin G. ;
Tsioufis, Konstantinos P. .
EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2020, 80 :1-11
[3]  
Bove M, 2017, VASC HEALTH RISK MAN, V13, P23, DOI 10.2147/VHRM.S115080
[4]   Effects of intensive urate lowering therapy with febuxostat in comparison with allopurinol on pulse wave velocity in patients with gout and increased cardiovascular risk: the FORWARD study [J].
Desideri, Giovambattista ;
Rajzer, Marek ;
Gerritsen, Martijn ;
Nurmohamed, Michael T. ;
Giannattasio, Cristina ;
Tausche, Anne-Kathrin ;
Borghi, Claudio .
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2022, 8 (03) :236-242
[5]   Decreased extra-renal urate excretion is a common cause of hyperuricemia [J].
Ichida, Kimiyoshi ;
Matsuo, Hirotaka ;
Takada, Tappei ;
Nakayama, Akiyoshi ;
Murakami, Keizo ;
Shimizu, Toru ;
Yamanashi, Yoshihide ;
Kasuga, Hiroshi ;
Nakashima, Hiroshi ;
Nakamura, Takahiro ;
Takada, Yuzo ;
Kawamura, Yusuke ;
Inoue, Hiroki ;
Okada, Chisa ;
Utsumi, Yoshitaka ;
Ikebuchi, Yuki ;
Ito, Kousei ;
Nakamura, Makiko ;
Shinohara, Yoshihiko ;
Hosoyamada, Makoto ;
Sakurai, Yutaka ;
Shinomiya, Nariyoshi ;
Hosoya, Tatsuo ;
Suzuki, Hiroshi .
NATURE COMMUNICATIONS, 2012, 3
[6]   Direct Radical Scavenging Activity of Benzbromarone Provides Beneficial Antioxidant Properties for Hyperuricemia Treatment [J].
Kadowaki, Daisuke ;
Sakaguchi, Shoichi ;
Miyamoto, Yohei ;
Taguchi, Kazuaki ;
Muraya, Nanako ;
Narita, Yuki ;
Sato, Keizo ;
Chuang, Victor Tuan Giam ;
Maruyama, Tom ;
Otagiri, Masaki ;
Hirata, Sumio .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2015, 38 (03) :487-492
[7]   Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout [J].
Kang, Eun Ha ;
Park, Eun Hye ;
Shin, Anna ;
Song, Jung Soo ;
Kim, Seoyoung C. .
EUROPEAN HEART JOURNAL, 2021, 42 (44) :4578-+
[8]   The future of febuxostat after the Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) trial: who CARES? [J].
Katsiki, Niki ;
Borghi, Claudio .
EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (17) :1853-1856
[9]   Cardiovascular Risks of Probenecid Versus Allopurinol in Older Patients With Gout [J].
Kim, Seoyoung C. ;
Neogi, Tuhina ;
Kang, Eun Ha ;
Liu, Jun ;
Desai, Rishi J. ;
Zhang, MaryAnn ;
Solomon, Daniel H. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (09) :994-1004
[10]   Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial [J].
Mackenzie, Isla S. ;
Ford, Ian ;
Nuki, George ;
Hallas, Jesper ;
Hawkey, Christopher J. ;
Webster, John ;
Ralston, Stuart H. ;
Walters, Matthew ;
Robertson, Michele ;
De Caterina, Raffaele ;
Findlay, Evelyn ;
Perez-Ruiz, Fernando ;
McMurray, John J. V. ;
MacDonald, Thomas M. .
LANCET, 2020, 396 (10264) :1745-1757
12